Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] Mechanisms of acquired BRAF inhibitor resistance in melanoma: a systematic review
I Proietti, N Skroza, N Bernardini, E Tolino, V Balduzzi… - Cancers, 2020 - mdpi.com
Simple Summary Patients with advanced melanoma are often treated with v-raf murine
sarcoma viral oncogene homolog B1 (BRAF) inhibitors. Although these agents prolong life …
sarcoma viral oncogene homolog B1 (BRAF) inhibitors. Although these agents prolong life …
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three …
PURPOSE Limited prospective data are available on sequential immunotherapy and
BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma. METHODS SECOMBIT is …
BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma. METHODS SECOMBIT is …
Sicca/Sjögren syndrome triggered by PD-1/PD-L1 checkpoint inhibitors: data from the International Immunocancer Registry (ICIR)
Objective: To analyse the worldwide occurrence of sicca/Sjögren (SjS) syndrome associated
with the use of immune checkpoint inhibitors (ICI) in patients with cancer. Methods: The …
with the use of immune checkpoint inhibitors (ICI) in patients with cancer. Methods: The …
The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta …
H Xu, X Xu, W Ge, J Lei, D Cao - Therapeutic Advances in …, 2020 - journals.sagepub.com
Background: Immune-related adverse events (irAEs) are common during immune
checkpoint inhibitor (ICI) treatment and reported to be associated with good survival. This …
checkpoint inhibitor (ICI) treatment and reported to be associated with good survival. This …
[HTML][HTML] The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic …
Simple Summary Drug–drug interactions (DDIs) risk is quite common, potentially significant,
and often underestimated. In this context, an advanced DDI detection software (Drug-PIN, V …
and often underestimated. In this context, an advanced DDI detection software (Drug-PIN, V …
Concurrent Vogt–Koyanagi–Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma
T Gambichler, C Seifert, M Lehmann, C Lukas… - …, 2020 - Taylor & Francis
Background: Vogt–Koyanagi–Harada disease (VKHD)-like symptoms have previously been
reported in 11 melanoma patients treated with immune checkpoint inhibitors. Materials & …
reported in 11 melanoma patients treated with immune checkpoint inhibitors. Materials & …
Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy
F Consoli, AM Manganoni, S Grisanti, F Petrelli… - PLoS …, 2019 - journals.plos.org
Panniculitis and vitiligo-like lesions have been recently identified as rare cutaneous side
effects of the combination of BRAF and MEK inhibitors, a standard of care in metastatic and …
effects of the combination of BRAF and MEK inhibitors, a standard of care in metastatic and …
Pharmacologically induced uveitis
MEAA Elsayed, I Kozak - Survey of Ophthalmology, 2021 - Elsevier
Treatments of numerous systemic and local diseases of different etiologies may be
accompanied by an unwanted side effect in the form of uveitis. We inform readers about …
accompanied by an unwanted side effect in the form of uveitis. We inform readers about …
Clinical proteomics of metastatic melanoma reveals profiles of organ specificity and treatment resistance
L Beck, M Harel, S Yu, E Markovits, B Boursi… - Clinical cancer …, 2021 - aacrjournals.org
Purpose: Treatment of metastatic melanoma has dramatically improved in recent years,
thanks to the development of immunotherapy and BRAF-MEK–targeted therapies. However …
thanks to the development of immunotherapy and BRAF-MEK–targeted therapies. However …
[HTML][HTML] Prescription patterns, recurrence, and toxicity rates of adjuvant treatment for stage III/IV melanoma—a real world single-center analysis
Simple Summary Adjuvant treatment with the immune checkpoint inhibitors (ICI)
pembrolizumab or nivolumab, or the targeted therapies dabrafenib and trametinib is …
pembrolizumab or nivolumab, or the targeted therapies dabrafenib and trametinib is …